Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors von Wakelee, H.A., Patnaik, A., Sikic, B.I., Mita, M., Fox, N.L., Miceli, R., Ullrich, S.J., Fisher, G.A., Tolcher, A.W.

Volltext

Mechanisms of Action of and Resistance to Antitubulin Agents: Microtubule Dynamics, Drug Transport, and Cell Death von DUMONTET, C, SIKIC, B. I

Volltext

Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein von DIMARTINO, I. F, LACAYO, N. J, VARADI, M, LI, L, SARAIYA, C, RAVINDRANATH, Y, YU, R, SIKIC, B. I, RAIMONDI, S. C, DAHL, G. V

Volltext

Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein von SIKIC, B. I, FISHER, G. A, LUM, B. L, HALSEY, J, BEKETIC-ORESKOVIC, L, CHEN, G

Volltext

Modulation of multidrug resistance: at the threshold von Sikic, B I

Volltext

Phase I Study of an Antisense Oligonucleotide to Protein Kinase C-α (ISIS 3521/CGP 64128A ) in Patients with Cancer von YUEN, A. R, HALSEY, J, FISHER, G. A, HOLMLUND, J. T, GEARY, R. S, KWOH, T. J, DORR, A, SIKIC, B. I

Volltext

A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance von Advani, R., Lum, B. L., Fisher, G. A., Halsey, J., Chin, D. L., Jacobs, C. D., Sikic, B. I.

Volltext

Significance of MicroRNAs in determining taxane resistance in ovarian cancer von Sultan, A, Kiet, T, Chan, J, Wang, Y, Duran, G, Francisco, B, Sikic, B

Volltext

Multidrug Resistance (mdrl) Gene Expression in Adult Acute Leukemias: Correlations With Treatment Outcome and In Vitro Drug Sensitivity von Marie, Jean-Pierre, Zittoun, Robert, Sikic, Branimir I.

Volltext

Pharmacological considerations in the modulation of multidrug resistance von Fisher, G.A., Lum, B.L., Hausdorff, J., Sikic, B.I.

Volltext

Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance von LUM, BL, KAUBISCH, S, YAHANDA, AM, ADLER, KM, JEW, L, EHSAN, MN, BROPHY, NA, HALSEY, J, GOSLAND, MP, SIKIC, BI

Volltext

Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance von BARTLETT, N. L, LUM, B. L, FISHER, G. A, BROPHY, N. A, EHSAN, M. N, HALSEY, J, SIKIC, B. I

Volltext

Integrated genomic analyses of ovarian carcinoma von Cancer Genome Atlas Research Network, The, Neuvial, Pierre

Volltext

NFKBIA Deletion in Glioblastomas von Bredel, Claudia, Bredel, Markus, Scholtens, Denise M, Yadav, Ajay K, Alvarez, Angel A, Renfrow, Jaclyn J, Chandler, James P, Yu, Irene L.Y, Carro, Maria S, Dai, Fangping, Tagge, Michael J, Ferrarese, Roberto, Phillips, Heidi S, Lukac, Paul J, Robe, Pierre A, Weyerbrock, Astrid, Vogel, Hannes, Dubner, Steven, Mobley, Bret, He, Xiaolin, Scheck, Adrienne C, Sikic, Branimir I, Aldape, Kenneth D, Chakravarti, Arnab, Harsh, Griffith R

Volltext

A Phase I Trial of Doxorubicin, Paclitaxel, and Valspodar (PSC 833), a Modulator of Multidrug Resistance von ADVANI, Ranjana, FISHER, George A, LUM, Bert L, HAUSDORFF, John, HALSEY, Joanne, LITCHMAN, Manuel, SIKIC, Branimir I

Volltext

MDR1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells von CHEN, G. K, DURAN, G. E, MANGILI, A, BEKETIC-ORESKOVIC, L, SIKIC, B. I

Volltext

A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C α, administered as a 21‐day infusion to patients with advanced ovarian carcinoma von Advani, Ranjana, Peethambaram, Prema, Lum, Bert L., Fisher, George A., Hartmann, Lynn, Long, Harry J., Halsey, Joanne, Holmlund, Jon T., Dorr, Andrew, Sikic, Branimir I.

Volltext

Multidrug resistance in lymphomas von Yuen, A R, Sikic, B I

Volltext

Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance von YAHANDA, AM, ADLER, KM, FISHER, GA, BROPHY, NA, HALSEY, J, HARDY, RI, GOSLAND, MP, LUM, BL, SIKIC, BI

Volltext

New approaches in cancer treatment von SIKIC, B. I

Volltext